Market Intelligence, Clinical Progress, and High-Purity Reagents for Vascular Normalization, Stability, and Angiogenesis Modulator Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ANGPT1/TIE2 axis drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ANGPT1 Recombinant Protein (WT & Mutants) High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View ANGPT1 Products |
| Receptor | TIE2 (TEK) ECD-Fc Fusion Protein Primary receptor for ANGPT1; critical for binding assays. Receptor ectodomain for ligand-receptor binding studies. Sequence Verified, >95% purity. |
View TIE2 Products |
| Gene Delivery | ANGPT1 Promise-ORF / Lentivirus Premade Particles Full-length ORF for stable cell line construction and secretion modeling. |
View ANGPT1 Products |
| Benchmark Ab | Anti-ANGPT1 (Sequence of Trebananib/Peptibody) Recombinant positive control for detection and neutralization assays. |
View ANGPT1 Products |
| Validator | ANGPT1 siRNA Set For knockdown verification and specificity controls. |
View ANGPT1 Products |
| Counter-Screen / Related Target A | ANGPT2 Recombinant Protein Context-dependent antagonist of TIE2; required for selectivity/counter-screening. HEK293 expressed, >95% purity. |
View ANGPT2 Products |
| Related Target B | VEGFA Recombinant Protein Parallel angiogenesis pathway for combination and synergy studies. |
View VEGFA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Glycosylation-Dependent Oligomerization | HEK293 Expression ensures native glycosylation; High Purity (>95%) preserves theoretical MW. |
| ANGPT1 vs ANGPT2 Selectivity Screening | Homolog panel proteins strictly verified by mass spec and sequence analysis; >95% purity for reliable SPR/BLI. |
| Cross-Species Cyno/Mouse Evaluation | Human / Cynomolgus / Mouse ortholog proteins available with endotoxin control. |
| Lack of Reliable Pathway Controls | Clinical Benchmark Antibodies/Peptibodies and validated siRNA included as sequence-verified standards. |
| Cell-Based TIE2 Signaling Readouts | Lentivirus for stable TIE2-expressing cell lines preserving native receptor conformation. |
| In Vitro Endothelial Cell Sensitization | Endotoxin Controlled (<1 EU/µg) proteins prevent false inflammatory responses. |
Live ANGPT1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ANGPT1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to bispecific pathway modulators and engineered protein mimetics. As an obligate agonist of the TIE2 receptor, ANGPT1 is central to vascular stabilization and permeability control. While first-generation therapies broadly targeted the Angiopoietin axis (often cross-reacting with ANGPT2) for oncology, the next wave of R&D is targeting highly selective ANGPT1 mimetics for acute respiratory distress syndrome (ARDS), sepsis, diabetic retinopathy, and inflammatory conditions. Furthermore, tumor-targeting therapies now require strict selectivity profiling to neutralize ANGPT2 while sparing the stabilizing effects of ANGPT1, driving massive demand for highly purified, structurally intact ANGPT1 assay reagents. The industry is moving beyond VEGF-centric approaches toward vessel normalization, with TIE2 activators and ANGPT2 blockers gaining traction for vascular leakage indications.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Recombinant ANGPT1 Mimetics / Fc-Fusion | Biotech Startups, Academic Spin-offs, Regenerative Medicine Biotechs | ARDS, Ischemic Stroke, Sepsis, Diabetic Nephropathy, IPF | Oligomerization Analysis (Need mammalian-expressed, endotoxin-free ANGPT1) |
| TIE2 Agonist (Peptide / Antibody) | Pharma / Emerging Biotech | Solid Tumors (Vessel Normalization), DME | Receptor Binding (Need native-folded ANGPT1 as reference ligand for SPR/BLI) |
| ANGPT2 / VEGF Bispecific | Roche (Faricimab), Regeneron | nAMD, Diabetic Retinopathy, Solid Tumors | Counter-Screening (Need ANGPT2 and ANGPT1 selectivity panels) |
| Peptibodies | Amgen (Trebananib) | Ovarian Cancer (Historically) | Binding Assays (Need sequence-verified TIE2 ECD-Fc and ANGPT1 standards) |
| Gene Therapy | Various | Peripheral Arterial Disease | Expression Validation (Need specific anti-ANGPT1 antibodies and siRNA) |
| VE-PTP Inhibitor (TIE2 Activator) | Specialty Pharma | Vascular Leakage, Glaucoma | Cell-Based Signaling (Need TIE2 lentivirus stable lines for pTIE2 assays) |